Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.
Introduction

67
The prevalence of type 2 diabetes (T2DM) continues to increase across the world [1] [2] [3] 68 and obesity is an important risk factor for T2DM. Non alcoholic fatty liver disease (NAFLD) men and 15-20% in women [6] , and in T2DM prevalence is as high as 70% [7] . The presence 74 of NAFLD is associated with increased risk of T2DM in the majority of studies [5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . 75 However, in these studies relative risk of T2DM varied markedly from a relatively small 64% 76 increase [15] , to a large 5.5 fold increase in risk [9] . This wide inter-study variation in risk of 77 incident T2DM, suggests that variation in other risk factors associated with NAFLD, such as 78 obesity, MetS, insulin resistance and inflammation, may be accounting for the marked 79 differences in risk of T2DM between these studies. Consequently, it is important to know how 80 obesity, with and without commonly associated risk factors such as NAFLD, inflammation,
81
MetS and insulin resistance, influences risk of T2DM.
82
Metabolically healthy obesity (MHO) is a term that has been used to define a group of 83 obese individuals who do not also have metabolic abnormalities although some studies have 84 still shown that subjects with MHO remain at higher risk of T2DM and cardiovascular disease 85 (CVD) than non-obese individuals [18] [19] [20] . Indeed, the variable risk of diabetes in MHO 86 subjects, may be explained by the different definitions that have been used to define MHO.
87
Previously, exclusion of MetS components, but not NAFLD, has been used to define MHO [21] , 88 and therefore it is not clear whether assessment of NAFLD status could contribute to a clinically 89 5 useful, pragmatic definition of MHO, that could be used to identify obese subjects who are at 90 low risk of developing diabetes.
91
In a large, well phenotyped obese cohort, our aim was to investigate incidence and risk of 92 T2DM in obese subjects with and without, fatty liver, inflammation, MetS components and 93 insulin resistance.
95
Materials and Methods
97
The study population consisted of individuals who participated in a comprehensive health (n = 219,417) . Among these subjects, we excluded subjects with missing body 100 mass index (BMI) data n = 7, non obese subjects, n = 157,478 (normal weight n = 95,408, 101 underweight n = 10,717, overweight n = 51,282). We also excluded subjects aged < 20 years
102
(n = 54), and subjects with heart disease, or stroke, subjects taking medication for stroke or 103 hyperlipidemia (n = 17,272), subjects with diabetes (n = 7,505), hypertension (n = 27,454),
104
history of cancer (n = 3,599) or with relevant missing data (n = 83) (N.B some subjects were 105 excluded for having more than one exclusion criterion). 
Results
178
The mean age ±SD (range) of the cohort was 37 ± 6 (range: 20-77) years. Table 1 and HOMA-IR, than subjects who did not develop diabetes during follow-up. Table 1 Baseline characteristics of the whole cohort according to incident DM Group B (n = 8,362 (28.03%) = obese subjects without features of the MetS [22] , but with ≥1 of fatty liver, IR, or inflammation (defined as above).
Group C (n = 1,717 (5.75%) = obese subjects without features of the MetS [22], fatty liver, IR or inflammation (defined as above). Log(-log S(t))
Supplementary figure 1. Graphical analysis to test proportional hazards assumption for t hree obesity groups and risk of incident diabetes over time
